Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 187

1.

Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: an analysis of 215 cases from the Malmö Diet and Cancer Study.

Jonsson L, Bergman J, Nodin B, Manjer J, Pontén F, Uhlén M, Jirström K.

J Transl Med. 2011 Jul 21;9:114. doi: 10.1186/1479-5876-9-114.

2.

High MCM3 expression is an independent biomarker of poor prognosis and correlates with reduced RBM3 expression in a prospective cohort of malignant melanoma.

Nodin B, Fridberg M, Jonsson L, Bergman J, Uhlén M, Jirström K.

Diagn Pathol. 2012 Jul 17;7:82. doi: 10.1186/1746-1596-7-82.

3.

Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer.

Boman K, Segersten U, Ahlgren G, Eberhard J, Uhlén M, Jirström K, Malmström PU.

BMC Urol. 2013 Apr 8;13:17. doi: 10.1186/1471-2490-13-17.

4.

Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate.

Svobodová S, Browning J, MacGregor D, Pollara G, Scolyer RA, Murali R, Thompson JF, Deb S, Azad A, Davis ID, Cebon JS.

Eur J Cancer. 2011 Feb;47(3):460-9. doi: 10.1016/j.ejca.2010.09.042. Epub 2010 Nov 4.

PMID:
21115342
5.

Prognostic value of galectin-3 in primary cutaneous melanoma.

Buljan M, Šitum M, Tomas D, Milošević M, Krušlin B.

J Eur Acad Dermatol Venereol. 2011 Oct;25(10):1174-81. doi: 10.1111/j.1468-3083.2010.03943.x. Epub 2010 Dec 22.

PMID:
21175876
6.

Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer.

Ehlén A, Brennan DJ, Nodin B, O'Connor DP, Eberhard J, Alvarado-Kristensson M, Jeffrey IB, Manjer J, Brändstedt J, Uhlén M, Pontén F, Jirström K.

J Transl Med. 2010 Aug 20;8:78. doi: 10.1186/1479-5876-8-78.

7.

Low RBM3 protein expression correlates with clinical stage, prognostic classification and increased risk of treatment failure in testicular non-seminomatous germ cell cancer.

Olofsson SE, Nodin B, Gaber A, Eberhard J, Uhlén M, Jirström K, Jerkeman M.

PLoS One. 2015 Mar 26;10(3):e0121300. doi: 10.1371/journal.pone.0121300. eCollection 2015.

8.

High expression of RNA-binding motif protein 3 in esophageal and gastric adenocarcinoma correlates with intestinal metaplasia-associated tumours and independently predicts a reduced risk of recurrence and death.

Jonsson L, Hedner C, Gaber A, Korkocic D, Nodin B, Uhlén M, Eberhard J, Jirström K.

Biomark Res. 2014 Jun 17;2:11. doi: 10.1186/2050-7771-2-11. eCollection 2014.

9.

Metallothionein-overexpression as a prognostic factor for progression and survival in melanoma. A prospective study on 520 patients.

Weinlich G, Bitterlich W, Mayr V, Fritsch PO, Zelger B.

Br J Dermatol. 2003 Sep;149(3):535-41.

PMID:
14510986
10.

Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer.

Jögi A, Brennan DJ, Rydén L, Magnusson K, Fernö M, Stål O, Borgquist S, Uhlen M, Landberg G, Påhlman S, Pontén F, Jirström K.

Mod Pathol. 2009 Dec;22(12):1564-74. doi: 10.1038/modpathol.2009.124. Epub 2009 Sep 4.

11.

Prognostic relevance of P-cadherin expression in melanocytic skin tumours analysed by high-throughput tissue microarrays.

Bauer R, Wild PJ, Meyer S, Bataille F, Pauer A, Klinkhammer-Schalke M, Hofstaedter F, Bosserhoff AK.

J Clin Pathol. 2006 Jul;59(7):699-705. Epub 2006 Mar 24.

12.

Expression of CD10 predicts tumor progression and unfavorable prognosis in malignant melanoma.

Oba J, Nakahara T, Hayashida S, Kido M, Xie L, Takahara M, Uchi H, Miyazaki S, Abe T, Hagihara A, Moroi Y, Furue M.

J Am Acad Dermatol. 2011 Dec;65(6):1152-60. doi: 10.1016/j.jaad.2010.10.019. Epub 2011 Jun 23.

PMID:
21700362
13.

Comparison of metallothionein-overexpression with sentinel lymph node biopsy as prognostic factors in melanoma.

Weinlich G, Topar G, Eisendle K, Fritsch PO, Zelger B.

J Eur Acad Dermatol Venereol. 2007 May;21(5):669-77.

PMID:
17447982
14.

Modifying effect of gender on the prognostic value of clinicopathological factors and Ki67 expression in melanoma: a population-based cohort study.

Fridberg M, Jonsson L, Bergman J, Nodin B, Jirström K.

Biol Sex Differ. 2012 Jul 2;3(1):16. doi: 10.1186/2042-6410-3-16.

15.

Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer.

Borgquist S, Jögi A, Pontén F, Rydén L, Brennan DJ, Jirström K.

Breast Cancer Res. 2008;10(5):R79. doi: 10.1186/bcr2146. Epub 2008 Sep 22.

16.

Functional and prognostic relevance of the homeobox protein MSX2 in malignant melanoma.

Gremel G, Ryan D, Rafferty M, Lanigan F, Hegarty S, Lavelle M, Murphy I, Unwin L, Joyce C, Faller W, McDermott EW, Sheahan K, Ponten F, Gallagher WM.

Br J Cancer. 2011 Aug 9;105(4):565-74. doi: 10.1038/bjc.2011.249. Epub 2011 Jul 5.

17.

Incident urothelial cancer in the Malmö Diet and Cancer Study: cohort characteristics and further validation of ezrin as a prognostic biomarker.

Wennersten C, Andersson G, Boman K, Nodin B, Gaber A, Jirström K.

Diagn Pathol. 2014 Oct 3;9:189. doi: 10.1186/s13000-014-0189-5.

18.

High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression.

Jonsson L, Gaber A, Ulmert D, Uhlén M, Bjartell A, Jirström K.

Diagn Pathol. 2011 Sep 28;6:91. doi: 10.1186/1746-1596-6-91.

19.
20.

Podocalyxin-like and RNA-binding motif protein 3 are prognostic biomarkers in urothelial bladder cancer: a validatory study.

Boman K, Andersson G, Wennersten C, Nodin B, Ahlgren G, Jirström K.

Biomark Res. 2017 Mar 14;5:10. doi: 10.1186/s40364-017-0090-y. eCollection 2017.

Supplemental Content

Support Center